Table 1.

Applied biomarker panel

Marker	Source/clone	Pretreatment	Dilution	Incubation	Other	Cutoff (AUROC or reference)
bcl2	Ventana/Roche 790-4604	CC1 16′	RTU	12′		70 % [34, 46]
bcl6	Ventana/Roche 760-4241	CC1 32′	RTU	28′		30 % [30]
c-myc	Ventana/Roche 790-4628	CC1 92′	RTU	16′, 37 °C		40 % [34, 46]
CD5	Ventana/Roche 790-4451	CC1 24′	RTU	12′		20 % (0.542)
CD10	Ventana/Roche 790-4506	CC1 24′	RTU	16′		20 % [29]
CD95	Leica NCL-FAS-310	PC 120 °C, 3′, citrate buffer pH 6	1:400	60′, 20 °C		1 % (0.613)
CD168	Leica NCL-CD168	CC1 extended 92′	1:200	32′	Biotin blocker	10 % (0.536)
					Amplification
Cyclin E	Thermo MS-1060-S	MW 98 °C, 30′, citrate buffer pH 6	1:20	Overnight, 4 °C		12 % (0.669)
FOXP1	Ventana/Roche 760-4611	CC1 16′	RTU	12′		50 % [45]
GCET	Abcam Ab68889	CC1 32′	1:25	20′		60 % [29]
LMO2	Ventana/Roche 790-4368	CC1 32′	RTU	16′		30 % [29]
MUM1p	Ventana/Roche 760-4529	CC1 24′	RTU	16′		70 % [29]
pSTAT3	Cell Signaling 9145	MW 98 °C, 30′, TEC buffer pH 8	1:50	Overnight, 4 °C	Biotin blocker	17 % (0.602)
BCL2 BAP	Abbott/Vysis 07 J75-001	Exactly as described [31]				>3 % [31]
C-MYC BAP	Abbott/Vysis 05 J91-001					>4 % [31]
MYC/IGH DFP	Abbott/Vysis 05 J75-001					>6.5 % [31]
EBER	Ventana/Roche 760-1209	According to the manufacturer’s protocol				10 %

For diagnostic purposes and to “subtract” CD3-positive T cells in CD5-positive DLBCL, CD3 and CD20 stainings were also performed, but these were not considered biomarkers sensu stricto